<DOC>
	<DOCNO>NCT00287157</DOCNO>
	<brief_summary>Nightly administration unique , sublingual ( tongue ) formulation tizanidine , know anti-spasticity medication , show previous study improve sleep next-day functioning CP ( cerebral palsy ) patient . It hypothesize improvement sleep efficiency ( i.e. , few wake episode , long time asleep , etc . ) result improvement quality-of-life ( i.e. , improvement next-day functioning , cognition movement ) may also see similar patient population , i.e. , child traumatic brain injury ( TBI ) .</brief_summary>
	<brief_title>Pilot , Proof-of-Concept Study Sublingual Tizanidine Children With Chronic Traumatic Brain Injury ( TBI )</brief_title>
	<detailed_description>Sublingual tizanidine , novel test formulation know effective antispasticity agent , show unique pharmacokinetic profile [ ( i.e. , nearly twice bioavailability/AUC ) , little increase peak plasma level ( Cmax ) , compare oral tizanidine ( Zanaflex ) ] . When administer nightly CP ( Cerebral Palsy ) patient effectively reduce muscle spasm disrupt sleep , show improve sleep efficiency , decrease sleep fragmentation improve sleep cycle . This improvement night-time sleep translate potential improvement next-day functioning ( improvement next-day measure spasticity movement ) . It hypothesize similar type improvement sleep consequent positive impact next day improvement spasticity , cognition function , may also manifest similar patient population , child traumatic brain injury .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<mesh_term>Tizanidine</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Males/Females 818 year age document history TBI Documented Loss Consciousness ( LOC ) 24 H , initial GCS ( Glasgow Coma Score ) low 8 Current Spasticity interfere task performance Patient able cooperate understand general explanation History allergy tizanidine inactive component ( include lactose intolerance ) Use hypnotic medication within 3 day baseline visit study Botox therapy within 6 week baseline , use Baclofen pump trial Use CYP1A2 inhibitor ( ex . ciprofloxacin fluvoxamine ) duration study Female patient oral contraceptive Significant abnormality clinical screen laboratory parameter ( ALT , AST , Bilirubin &gt; 2 x uln ; Creatinine &gt; 2 mg/dl ; WBC &lt; 2300/mm3 , platelet &lt; 80,000/mm3 ) Taking medication may adversely interfere action study medication outcome variable within 2 week 5 halflives baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Traumatic Brain Injury</keyword>
	<keyword>Actigraphy</keyword>
	<keyword>Spasticity , Cognition Functioning</keyword>
</DOC>